STAT3 Mutations Linked to Rare Leukemia 
MedPage Today
LGLL is a rare disease in which large granular lymphocytes -- positive for the CD3, CD8, and CD57 proteins -- infiltrate the bone marrow, spleen, liver, and blood. Many patients also develop autoimmune disorders. All in all, Mustjoki and colleagues ...

and more » 

Cellerant Announces Publication Demonstrating Significant Survival Benefits ... 
MarketWatch (press release)
SAN CARLOS, Calif., May 14, 2012 (BUSINESS WIRE) -- Cellerant Therapeutics, Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced the publication of a ...

and more » 

ASH Agenda for Hematology Research Identifies Most Promising Areas for ... 
MarketWatch (press release)
The American Society of Hematology (ASH), the world's largest professional society committed to the study and treatment of blood disorders, today issued a report urging federal agencies to coordinate hematology research funding around seven specific ...

and more » 

Dr. David Nathan M.D. of Cambridge Receives Clarkson University Honorary Degree 
ReadMedia (press release)
The degree was awarded for his "his role as a dedicated physician and medical research pioneer, whose advances in research have had a profound and lasting impact on our understanding and treatment of hematological diseases and cancer; and for his role ...

and more » 

Medina Hospital opens suite for cancer treatment 
WKYC-TV
Physicians and registered nurses will treat solid tumor and hematological disorders, as well as perform blood transfusions. Medina Hospital President Thomas Tulisiak, MD said "With the opening of Medina Hospital's new infusion suite, Medina County ...

 

Pfizer To Present New Data In Advanced Kidney, Lung And Hematologic Cancers At ... 
FiercePharma
New data will be presented on targeted cancer treatments from the Pfizer Oncology portfolio across three key therapeutic categories, including tumors of the kidney, lung and hematologic malignancies, at the Annual Meeting of the American Society of ...

and more » 

Onconova Advances Oral Rigosertib to Phase II Clinical Trial in ... 
MarketWatch (press release)
MDS and AML are blood disorders widely recognized as difficult to manage, with limited therapeutic options available for patients, especially those with drug-resistant disease. The multi-site Phase III ONTIME (ClinicalTrials.gov identifier, ...

and more » 

Onconova Advances Oral Rigosertib to Phase II Clinical Trial in ... 
EON: Enhanced Online News (press release)
MDS and AML are blood disorders widely recognized as difficult to manage, with limited therapeutic options available for patients, especially those with drug-resistant disease. The multi-site Phase III ONTIME (ClinicalTrials.gov identifier, ...

and more » 

Positive Phase 2 Clinical Data with Tivantinib in Hepatocellular Carcinoma to ... 
MarketWatch (press release)
Data from the HCC trial demonstrated a statistically significant improvement in time-to-progression (HR=0.43, log rank p-value=0.03), accompanied by significant improvements in progression-free survival and disease control rate among second-line ...

and more » 

Research and Markets: Partnerships, Licensing, Investments and M&A Deals and ... 
PharmiWeb.com (press release)
Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, ...

and more »